SCHEMBL15901388

SCHEMBL15901388

CCOc1ccc(Br)c(OC)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MBOAT4 Q96T53 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
BTK Q06187 1/20 0.36
CCR4 P51679 1/20 0.35
MAPT P10636 1/20 0.35
MAPK8 P45983 1/20 0.35
HTT P42858 2/20 0.34
ADORA1 P30542 3/20 0.34
PDE10A Q9Y233 1/20 0.34
ADORA2A P29274 2/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
ACACB O00763 1/20 0.32
NQO1 P15559 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9931250 0.89 HPGD (0.43) HPGDSMN1; SMN2TDP1BTKMAPT
SCHEMBL15908315 0.86 ALDH1A1 (0.37) HPGDSMN1; SMN2MBOAT4POLBTDP1
SCHEMBL29850137 0.82 POLB (0.50) HPGDSMN1; SMN2MBOAT4POLBTDP1
SCHEMBL1460108 0.82 POLB (0.50) HPGDSMN1; SMN2MBOAT4POLBTDP1
SCHEMBL20360842 0.81 BTK (0.40) HPGDSMN1; SMN2MBOAT4POLBTDP1
SCHEMBL20203884 0.80 L3MBTL1 (0.39) SMN1; SMN2MBOAT4POLBTDP1ADORA2A
SCHEMBL21585396 0.79 POLB (0.37) SMN1; SMN2POLBTDP1BTKCCR4
SCHEMBL21582525 0.78 MAPT (0.39) HPGDSMN1; SMN2POLBTDP1CCR4
SCHEMBL16783076 0.77 BTK (0.37) HPGDSMN1; SMN2TDP1BTKMAPT
SCHEMBL19461628 0.77 PDE2A (0.44) SMN1; SMN2POLBADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4660182-A1 NAV1.7- AND/OR NAV1.8-INHIBITING ARYL PYRIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS Eurofarma Laboratórios S.A. (BR) 2025-12-10 EP disclosed
EP-2948442-B1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2016-10-26 EP disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 US disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 US disclosed
US-8877741-B2 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-04 US disclosed
US-20140213568-A1 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-31 US disclosed
US-20140213568-A1 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213568-A1 Pyrrolidine derivatives, pharmaceutical compositions and uses thereof PEPD, PGA5, PYCR1 HPGD 26/4885SMN1; SMN2 4379/4885MBOAT4 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.